SCHEMBL25905366

SCHEMBL25905366

CC(=O)c1ccnc(C(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 1/20 0.44
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
RAF1 P04049 6/20 0.39
BRAF P15056 6/20 0.39
CYP2A6 P11509 1/20 0.39
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4C Q9H3R0 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KDM6B O15054 1/20 0.37
TET3 O43151 1/20 0.37
KDM4A O75164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6637819 0.87 MEN1 (0.39) PROKR1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL1759894 0.85 KDM4C (0.55) PROKR1ALDH1A1KDM4CMAPTKDM4E
SCHEMBL12136051 0.83 SMARCA2 (0.49) MEN1KMT2ARAF1BRAFALDH1A1
SCHEMBL30418990 0.83 KDM5C (0.44) PROKR1CYP1A2CYP3A4KDM4CKDM5A
SCHEMBL6047032 0.83 KDM5C (0.44) PROKR1CYP1A2CYP3A4KDM4CKDM5A
SCHEMBL13130439 0.80 PROKR1 (0.41) PROKR1KMT2ACYP1A2CYP3A4RAF1
SCHEMBL28298259 0.80 MEN1 (0.37) MEN1KMT2ACYP1A2CYP3A4RAF1
SCHEMBL14566838 0.80 PLK1 (0.46) PROKR1MEN1KMT2ARAF1BRAF
SCHEMBL8953772 0.80 KDM4E (0.57) PROKR1CYP1A2CYP3A4ALDH1A1NPC1
SCHEMBL30007857 0.79 KDM4E (0.50) PROKR1MEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 PROKR1 2271/4885MEN1 2201/4885KMT2A 2436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.